Albert Adell Calduch (IP)

  • IBBTEC. Albert Einstein 22, PCTCAN, 39011 Santander
  • albert.adell@unican.es
  • 942206857
  • Systems Neurobiology
  • Principal Investigator
  • Neuropharmacology
  • Department of Cell & Molecular Signalling

Albert Adell, PhD is Principal Investigator of the Systems Neurobiology Group at the Institute of Biomedicine and Biotechnology of Cantabria, a joint center Joint Centre belonging to the National Research Council (CSIC), the University of Cantabria, and the Regional Government through its Society for the Development of Cantabria (SODERCAN). Dr. Adell was awarded a Bachelor of Science degree in Biology from the University of Barcelona (1981) and a PhD degree in Biology from the same Institution (1986). In 1987 he earned a postdoctoral position at Professor Gerald Curzon's Lab at the Institute of Neurology (London, UK), where he learned the intricacies of the in vivo microdialysis technique that allows the measurement of neurotransmitters release in the brain of behaving animals. In 1990 he earned a position as tenured scientist from the Spanish National Research Council, and he started to study the mechanism of action of antidepressant drugs at the Institute of Biomedical Research of Barcelona. In 1991 he continued to study the role of raphe nuclei in the mechanism of action of antidepressant drugs as a Visiting Scientist at the Department of Pharmacology of the School of Medicine of the University of Gothenburg (Sweden). In 1993 he was appointed as Research Scholar at the Department of Pharmacology of the School of Medicine of the East Carolina University (NC, USA) where he spent two years teaching graduate students and studying the role of brain monoamines in alcohol addiction. Back to Spain in 1995, he continued to examine the effects of antidepressant and antipsychotic drugs on brain monoamines and behavior. In 2009 he promoted to Research Scientist from the Spanish National Research Council and eventually moved to the Institute of Biomedicine and Biotechnology of Cantabria in 2014. His main interest is the study of new molecular entities that can act as rapid-acting antidepressant drugs (RAADs).

Systems Neurobiology


Research interests

To study the effects of new fast-acting antidepressant treatments (deep brain stimulation [DBS], ketamine, subunit selective NMDA receptor antagonists) on the changes produced in animal models of depression. This includes the study in detail of the role of the projections from the prefrontal cortex to the monoaminergic nuclei of the brainstem in the pathophysiology of depression and its pharmacological treatment.

Funding

  • Instituto de Salud Carlos III, Subdirección General de Evaluación y Fomento de la Investigación (FIS Grants PI10-01103 and PI13-00038) that were co-funded by the European Regional Development Fund ("A way to build Europe").
  • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)

Effects of Acute Stress on the Oscillatory Activity of the Hippocampus-Amygdala-Prefrontal Cortex Network

Merino E, Raya-Salom D, Teruel-Martí V, Adell A, Cervera-Ferri A, Martínez-Ricós J.

Neuroscience. 2021 Sep 17:S0306-4522(21)00476-0. doi: 10.1016/j.neuroscience.2021.09.009. Online ahead of print.

View more

mTOR Knockdown in the Infralimbic Cortex Evokes A Depressive-like State in Mouse

mTOR Knockdown in the Infralimbic Cortex Evokes A Depressive-like State in Mouse

Garro-Martínez E, Fullana MN, Florensa-Zanuy E, Senserrich J, Paz V, Ruiz-Bronchal E, Adell A, Castro E, Díaz Á, Pazos Á, Bortolozzi A, Pilar-Cuéllar F.

Int J Mol Sci. 2021 Aug 12;22(16):8671. doi: 10.3390/ijms22168671.

View more

Structural connectivity and subcellular changes after antidepressant doses of ketamine and Ro 25-6981 in the rat: an MRI and immuno-labeling study

Pascual-Antón R, Blasco-Serra A, Muñoz-Moreno E, Pilar-Cuéllar F, Garro-Martínez E, Florensa-Zanuy E, López-Gil X, Campa VM, Soria G, Adell A.

​Brain Struct Funct. 2021 Aug 7. doi: 10.1007/s00429-021-02354-0.

View more

Cannabidiol antidepressant-like effect in the lipopolysaccharide model in mice: Modulation of inflammatory pathways

Florensa-Zanuy E, Garro-Martínez E, Adell A, Castro E, Díaz Á, Pazos Á, Mac-Dowell KS, Martín-Hernández D, Pilar-Cuéllar F.

​Biochem Pharmacol. 2021 Mar;185:114433. doi: 10.1016/j.bcp.2021.114433. Epub 2021 Jan 26.

View more

Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine.

López-Gil X, Jiménez-Sánchez L, Campa L, Castro E, Frago C, Adell A.

​ACS Chem Neurosci. 2019 Jul 17;10(7):3318-3326. doi: 10.1021/acschemneuro.9b00288. Epub 2019 Jun 18.​

View more

β-Catenin Role in the Vulnerability/Resilience to Stress-Related Disorders Is Associated to Changes in the Serotonergic System.

Garro-Martínez E, Vidal R, Adell A, Díaz Á, Castro E, Amigó J, Gutiérrez-Lanza R, Florensa-Zanuy E, Gómez-Acero L, Taketo MM, Pazos Á, Pilar-Cuéllar F.

Mol Neurobiol. 2019 Dec 10. doi: 10.1007/s12035-019-01841-0. [Epub ahead of print]

View more

Signaling pathways responsible for the rapid antidepressant-like effects of a GluN2A-preferring NMDA receptor antagonist.

Gordillo-Salas M, Pilar-Cuéllar F, Auberson YP, Adell A.

​Transl Psychiatry. 2018 Apr 18;8(1):84. doi: 10.1038/s41398-018-0131-9.​

View more

Behavioral, neurochemical and molecular changes after acute deep brain stimulation of the infralimbic prefrontal cortex.

Jiménez-Sánchez L, Linge R, Campa L, Valdizán EM, Pazos Á, Díaz Á, Adell A. Neuropharmacology. 2016 Sep;108:91-102. doi: 10.1016/j.neuropharm.2016.04.020

​https://www.ncbi.nlm.nih.gov/pubmed/?term=Behavioral%2C+neurochemical+and+molecular+changes+after+acute+deep+brain+stimulation+of+the+infralimbic+prefrontal+cor

View more

Characterization of oscillatory changes in hippocampus and amygdala after deep brain stimulation of the infralimbic prefrontal cortex.

Cervera-Ferri A, Teruel-Martí V, Barceló-Molina M, Martínez-Ricós J, Luque-García A, Martínez-Bellver S, Adell A.

[PubMed] Physiol Rep. 2016 Jul;4(14). pii: e12854. doi: 10.14814/phy2.12854.

View more

Activation of AMPA Receptors Mediates the Antidepressant Action of Deep Brain Stimulation of the Infralimbic Prefrontal Cortex.

Jiménez-Sánchez L, Castañé A, Pérez-Caballero L, Grifoll-Escoda M, López-Gil X, Campa L, Galofré M, Berrocoso E, Adell A. Cereb Cortex. 2016 Jun;26(6):2778-89. doi: 10.1093/cercor/bhv133.

[PubMed]

View more

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.

Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á. Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017.

[PubMed]

View more

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.

Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á.

​Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017. Epub 2015 Dec 19.

View more

Revisiting the role of raphe and serotonin in neuropsychiatric disorders.

Adell A. (2015) J Gen Physiol 145: 257-259.

[PubMed]

View more

The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression.

Jiménez-Sánchez L., Campa L., Auberson Y.P. and Adell A. (2014) Neuropsychopharmacology 39, 2673–2680.

[PubMed]

View more

Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action.

Mocci G., Jiménez-Sánchez L., Adell A. and Artigas F. (2014) Neuropharmacology 79: 49-58.

[PubMed]

View more

Blockade of MK-801-induced heat shock protein 72 in rat brain by antipsychotic and monoaminergic agents targeting D2, 5-HT1A, 5-HT2A and α1-adrenergic receptors.

Romón T., Planas A.M. and Adell A. (2014) CNS Neurol. Disord. – Drug Targets 13: 104-111.

[PubMed]

View more

Role of prefrontal cortex in the pathophysiology and treatment of depression and schizophrenia. In: Neurobiology of Mood Disorders.

López-Gil X., Jiménez-Sánchez L. and Adell A. (2013) Guiard B.P. and Dremencov E. (Eds.). Bentham Science Publishers, Sharjah, pp. 139-173.

View more

Importance of interhemispheric prefrontal connection in the effects of noncompetitive NMDA receptor antagonists.

López-Gil X., Jiménez-Sánchez L., Romón T., Campa L., Artigas F. and Adell A. (2012) Int. J. Neuropsychopharmacol. 15: 945-956.

[PubMed]

View more

Is the acute NMDA receptor hypofunction a valid model of schizophrenia?

Adell A., Jiménez-Sánchez L., López-Gil X. and Romón T. (2012) Schizophrenia Bull. 38: 9-14.

 [PubMed]

View more

Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia.

Romón T., Mengod G. and Adell A. (2011) Psychopharmacology 217: 231-238.

[PubMed]

View more

Microdialysis.

Adell A. and Artigas F. (2010) In: Encyclopedia of Psychopharmacology. Stolerman I.P. (Ed.). Springer-Verlag, Berlin, pp. 769-775.

View more

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

Adell A. (2010) Idrugs 13: 900-910.

[PubMed]

View more

In vitro and in vivo activation of astrocytes by amyloid β is potentiated by pro-oxidant agents.

García-Matas S., de Vera N., Ortega-Aznar A., Marimon J.M., Adell A., Planas A.M., Cristòfol R. and Sanfeliu C. (2010) J. Alzheimer's Dis. 20: 229-245.

[PubMed]

View more

Serotonin interaction with other transmitter systems. In: Handbook of Behavioral Neurobiology of Serotonin.

Adell A., Bortolozzi A., Díaz-Mataix L., Santana N. and Artigas F. (2010) Müller C.P. and Jacobs B.L. (Eds.). Elsevier, Amsterdam, pp. 259-276.

View more

Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.

López-Gil X., Artigas F. and Adell A. (2010) Curr. Pharm. Des. 16: 502-515.

[PubMed]

View more

New strategies in the search of antipsychotic drugs.

Adell A. (2010) Curr. Pharm. Des. 16: 486-487.

[PubMed]

View more